Agenus INC Form 4 insider transactions

Director Jennifer Buell received 869 shares of Agenus Inc. common stock as part of her salary, in lieu of cash, as approved by the Agenus Inc. Compensation Committee.

A Form 4 filing reveals Agenus Inc. CEO Garo H. Armen received 5,260 shares of common stock in lieu of cash salary for the pay period ending May 2, 2025, at a price of $3.11 per share.

Agenus Inc. CEO Garo H. Armen received 7,886 shares of common stock as compensation in lieu of cash salary for the pay period ending April 18, 2025.

Director Jennifer Buell received 1,159 shares of Agenus Inc. common stock as part of her compensation, in lieu of cash, as approved by the Agenus Inc. Compensation Committee.

Garo H. Armen, Chairman and CEO of Agenus Inc., received 10,288 shares of common stock as part of his salary in lieu of cash, according to a Form 4 filing.

Director Thomas L. Harrison acquired 8,898 shares of Agenus Inc. common stock on April 1, 2025, as part of the company's Board Compensation Election Policy.

Director Timothy Wright reports acquiring 3,255.585 deferred stock units of Agenus Inc. under the company's deferred compensation plan.

Director Jennifer Buell acquired 1,123 shares of Agenus Inc. common stock at $1.61 per share as part of her salary compensation plan.

Jennifer Buell, a director at Agenus Inc., acquired 409 shares of common stock as part of her salary compensation, while disposing of 15,646 shares.

Agenus Inc. CEO Garo Armen received 9,243 shares of common stock as compensation in lieu of cash salary for the pay period ending March 21, 2025.

Director Jennifer Buell acquired 545 shares of Agenus Inc. common stock as part of her salary compensation, according to a recent SEC filing.

Agenus Inc. CEO Garo Armen received 6,332 shares of common stock as payment for his salary for the pay period ending March 7, 2025, while also disposing of 148,383 shares.

Director Jennifer Buell receives Agenus Inc. stock in lieu of cash salary as part of the company's compensation plan.

Garo H. Armen, Chairman and CEO of Agenus Inc., received 4,483 shares of common stock in lieu of cash salary for the pay period ending February 21, 2025.

Director Jennifer Buell received 516 shares of Agenus Inc. common stock as part of her compensation, in lieu of cash, according to a recent SEC filing.

Agenus Inc. CEO Garo H. Armen received 4,251 shares of common stock as payment for his salary for the pay period ending February 7, 2025, while also disposing of 137,568 shares.

Director Jennifer Buell reports a stock transaction related to tax liability payment on stock received in lieu of cash salary.

Agenus Inc. director Jennifer Buell received 776 shares of common stock as part of her compensation in lieu of cash.

Agenus Inc. CEO Garo H. Armen received 4,169 shares of common stock in lieu of cash as part of his compensation for the pay period ending January 24, 2025.

A Form 4 filing reveals Agenus Inc. CEO Garo H. Armen received 4,777 shares of common stock at $3.12 per share as part of his salary compensation.

Director Timothy Wright reports acquiring 2,532.661 Deferred Stock Units of Agenus Inc. on January 2, 2025, under the company's Amended and Restated Directors' Deferred Compensation Plan.

Director Susan B. Hirsch reports acquiring deferred stock units convertible to common stock under Agenus Inc.'s compensation plan.

Agenus Inc. CEO Garo Armen received 5,931 shares of common stock as compensation in lieu of cash salary for the pay period ending December 27, 2024.

Agenus CEO Garo Armen received 5,347 shares of common stock as part of his salary for the pay period ending December 13, 2024.

Agenus CEO Garo Armen received 4,769 shares of common stock as part of his salary for the pay period ending November 29, 2024.

Christine Klaskin, PFO & PAO of Agenus Inc., was granted 10,000 stock options as a one-time retention award.

Agenus Inc. CEO Garo Armen received stock in lieu of cash salary and a one-time retention stock option award, according to a recent SEC filing.

Agenus Inc. executive Jennifer Buell was granted 300,000 stock options as a one-time retention award.

Agenus Inc.'s Chief Medical Officer, Steven J. O'Day, was granted 50,000 stock options as a one-time retention award.

A Form 4 filing reveals Agenus Inc. CEO Garo H. Armen received 4,207 shares of common stock as part of his compensation in lieu of cash.